Consider a long-term investment in Hims & Hers Health (HIMS), as the market may be undervaluing its strategic shift from sexual health into a comprehensive longevity and preventative care platform. The company is leveraging its AI-powered MedMatch technology to offer personalized, low-cost health solutions, positioning it as a key way to invest in the growing longevity theme. This disruptive focus on prevention poses a direct threat to the business models of traditional "sick care" companies. As a result, investors could consider a bearish stance on dialysis providers like DaVita (DVA) and Fresenius Medical Care (FMS). The core thesis is that as HIMS helps prevent chronic diseases, demand for treatment-focused services offered by companies like DVA and FMS may decline over the long term.

Hims & Hers Health, Inc. (HIMS)

• The speaker is extremely bullish on HIMS, identifying as a long-term, large shareholder. They believe the market misunderstands the company, creating an investment opportunity.
• The core investment thesis is that HIMS is evolving from a company known for sexual health (ED) and hair loss into a comprehensive longevity and preventative healthcare platform.
• The new Super Bowl ad is highlighted as a key indicator of this strategic shift.
  • The ad's theme is "longevity for all," positioning affordable health as its mission, in contrast to expensive, exclusive health services.
  • It focuses on future growth areas like GLP-1s (for weight loss), diagnostics, menopause, testosterone, and early cancer detection, while moving away from its legacy businesses.
• HIMS is seen as being "steps ahead" of competitors like Ro. While Ro focuses narrowly on GLP-1s, HIMS is already building the narrative for the "next big thing": longevity.
• The business model is built on three pillars:
  1. AI-Powered Personalization: Using its MedMatch AI platform and a growing dataset from nearly 2.4 million subscribers, HIMS aims to predict health issues before they arise and create customized, compounded medications.
  2. At-Home Diagnostics: The company offers comprehensive lab tests for $349. The future vision includes using technology from its acquisition of Tribe Labs for painless, at-home blood collection, which could increase demand.
  3. Cost Disruption: HIMS's digital-first model (no physical offices or pharmacies) and use of AI allows it to offer services much cheaper than the traditional "rent-seeking" healthcare system.

Takeaways

• Bullish Case: The primary insight is a strong bullish view on HIMS. The speaker believes the stock is undervalued because the market views it as a simple GLP-1 or ED company, failing to see its potential as a disruptive, AI-driven longevity platform.
• Long-Term Vision: Investors should look beyond current revenue streams (like sexual health) and focus on the company's long-term strategy in longevity, diagnostics, and personalized medicine. The Super Bowl ad is presented as a roadmap for this future.
• Competitive Edge: HIMS is positioned as a more innovative and forward-thinking company than its private competitor Ro, suggesting it is better positioned to win the telehealth market long-term.
• Risk Factor (Mentioned by Speaker): The speaker is admittedly "extremely biased" as a major shareholder, which is an important consideration for anyone evaluating this perspective.

Ro (Private Competitor)

• Ro is a private company and a direct competitor to HIMS. The speaker presents a critical view of its strategy.
• Ro's Super Bowl ad, featuring Serena Williams, is criticized for being:
  • Narrowly focused only on GLP-1 weight loss drugs.
  • Likely much more expensive than the HIMS ad due to the celebrity endorsement.
  • Potentially having "off" branding by using the name "Ro" (derived from Roman for men's health) to target women for weight loss.
• The speaker suggests that if Ro were a public company, the market would likely treat it purely as a GLP-1 play, making it vulnerable to news cycles in that specific category.

Takeaways

• This analysis serves as a competitive benchmark. The speaker argues that HIMS has a superior, more diversified, and forward-looking strategy compared to Ro.
• For investors in HIMS, Ro's perceived strategic weaknesses reinforce the bull case for HIMS as the leader in the space.

Investment Theme: Longevity

• The speaker identifies longevity as the "next big thing" in healthcare and a major investment theme that is going mainstream.
• This trend is being popularized by well-known figures like Bryan Johnson, Peter Attia, and Dr. David Sinclair.
• Currently, longevity services are extremely expensive (e.g., Bryan Johnson's routine costs $2 million/year; Peter Diamandis's service costs $20,000/year).
• HIMS is positioning itself to disrupt this by making longevity protocols and preventative care affordable and accessible to the general public.

Takeaways

• Investors interested in the growing longevity sector should consider HIMS as a way to get exposure.
• The company's strategy is to "democratize" longevity, moving it from a luxury for the rich to a service for the masses, which represents a massive total addressable market.

Investment Theme: AI in Healthcare

• The use of Artificial Intelligence (AI) is presented as a critical component of the HIMS investment thesis and a transformative force in healthcare.
• HIMS is leveraging AI (MedMatch) to analyze user data and:
  • Predict future health problems (similar to how Target predicted pregnancies based on shopping data).
  • Prescribe customized, compounded medications tailored to an individual's specific needs.
  • Automate processes to dramatically lower costs.
• The speaker believes that in the future, AI will be allowed to prescribe medications, which would unlock massive cost savings and efficiency across the entire healthcare system.

Takeaways

• HIMS can be viewed as an "AI in Healthcare" play. Its value is tied to its ability to build a large, proprietary dataset and use AI to create better, cheaper health outcomes.
• The long-term vision involves creating "digital twins" of patients where treatments can be tested virtually before being prescribed, representing a paradigm shift in medicine.

DaVita (DVA) & Fresenius Medical Care (FMS)

• These companies, which provide dialysis services for patients with kidney failure (often resulting from Type 2 diabetes), are mentioned as examples of the legacy "sick care" industry.
• The speaker argues that their business models rely on treating chronic diseases rather than preventing them.
• The HIMS model of early detection and prevention is a direct threat to these companies. For example, if HIMS uses AI and lab data to detect pre-diabetes in a 27-year-old and intervenes, that person may never become a diabetic patient who needs dialysis.

Takeaways

• Bearish Case: If you believe in the disruptive potential of preventative healthcare models like HIMS, you might adopt a bearish or cautious stance on legacy companies like DaVita (DVA) and Fresenius (FMS) whose profits depend on the prevalence of chronic disease.
• This highlights the broader theme of disruption, where new-era subscription and tech-based models are challenging established, transaction-based incumbents.